| Chemical Properties | Back Directory | [density ]
1.289±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 250 mg/mL (507.57 mM; Need ultrasonic) | [form ]
Solid | [pka]
4.88±0.10(Predicted) | [color ]
Light yellow to brown |
| Hazard Information | Back Directory | [Uses]
BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP4 receptor antagonist, with a pKB of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache[1]. | [Biological Activity]
BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP4 receptor antagonist, with a pKB of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache[1].
BGC-20-1531 free base competitively antagonized PGE2-induced vasodilatation of human middle cerebral (pKb=7.8) and meningeal (pKb=7.6) arteries, but had no effect on responses induced by PGE2 on coronary, pulmonary or renal arteries[1].
BGC-20-1531 free base (1-10 mg/kg; i.v.) causes a dose-dependent antagonism of the PGE2-induced increase in canine carotid blood flow[1]. | [in vivo]
BGC-20-1531 free base (1-10 mg/kg; i.v.) causes a dose-dependent antagonism of the PGE2-induced increase in canine carotid blood flow[1]. | Animal Model: | Beagle dogs[1] | | Dosage: | 1-10 mg/kg | | Administration: | I.v. | | Result: | Caused a dose-dependent antagonism of the PGE2-induced increase in canine carotid blood flow.
|
| [IC 50]
EP4: 7.6 (pKd) | [References]
[1]. Maubach KA, et al. BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009;156(2):316-327. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|